Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Investigating glatiramer acetate for relapsing–remitting multiple sclerosis at the double dose—is more better?

Nature Clinical Practice Neurology volume 3, pages 540–541 (2007)Cite this article

boxed-textCohen JA et al. (2007) Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS. Neurology 68: 939–944

The 40 mg/day dose of glatiramer acetate is not clinically available and further testing is warranted to determine whether this double dose has sustained clinical benefits and is safe and well tolerated

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Comi G et al. (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 49: 290–297

    Article  CAS  Google Scholar 

  2. Butovsky O et al. (2006) Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc Natl Acad Sci USA 103: 11784–11789

    Article  CAS  Google Scholar 

  3. Vieira PL et al. (2003) Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol 170: 4483–4488

    Article  CAS  Google Scholar 

  4. Bielekova B et al. (2000) Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 6: 1167–1175

    Article  CAS  Google Scholar 

  5. Comi G (2000) Why treat early multiple sclerosis patients? Curr Opin Neurol 13: 235–240

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Martina Habeck, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Johns Hopkins Hospital, 600 North Wolfe Street, Pathology 627, Baltimore, MD 21287–6965, USA pcalabr1@jhmi.edu

Authors and Affiliations

  1. PA Calabresi is Associate Professor of Neurology and Director of the Johns Hopkins Multiple Sclerosis Center, Baltimore, MD, USA.,

    Peter A Calabresi

Authors
  1. Peter A Calabresi
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author has acted as a consultant for and received grant/research support from Biogen Idec, Novartis, Serono and Teva Pharmaceutical Industries.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Calabresi, P. Investigating glatiramer acetate for relapsing–remitting multiple sclerosis at the double dose—is more better?. Nat Rev Neurol 3, 540–541 (2007). https://doi.org/10.1038/ncpneuro0612

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0612

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing